SLC25A13

Across TCGA pan-cancer cohorts, SLC25A13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC25A13 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC25A13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC25A13 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, PDAC, and GBM are the cancer types where SLC25A13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.862	0.122	.006	13	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	11	view →
GBM	OS	Median	All	0.416	0.639	.010	2	view →
CCRCC	DFS	Median	II,III,IV	0.612	0.787	.048	1	view →
LSCC	OS	Quartile	All	0.833	0.952	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC25A13–LUAD (DFS)

Open the LUAD breakdown →